Steven Anderson, PhD
Director, Office of Biostatistics and Pharmacovigilance, FDA CBER
Headed CBER's pharmacovigilance office and in September 2021 asked that Dr. Szarfman refrain from using her FDA email to communicate data mining findings using CBER VAERS data.
Timeline appearances (6)
- analysis
Niu emails Anderson about a meeting with Szarfman to discuss new methods for data mining.
- analysis
Szarfman presents RGPS to Marks and other CBER officials, calling MGPS not state of the art.
- internal
Szarfman confirms she has access to VAERS data through Oracle's Empirica.
- internal
Anderson asks Marks that Szarfman refrain from using FDA email or communicating findings using CBER VAERS data.
- internal
Marks tells Cavazzoni that Szarfman has been asked to cease and desist on her vaccine analysis.
- publication
Forshee notifies Marks and Anderson that FDA officials are addressing issues with Szarfman's published paper.
Quotes (1)
-
"we have concerns about her communicating data mining findings using CBER VAERS data to CBER and non-CBER personnel."